Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart;2-es típusú cukorbetegek szénhidrát- anyagcseréjének, cardiovascularis és alkati paramétereinek változása bifázisos humán inzulinról analóg premix inzulinra történt terápiaváltás után

Orvosi Hetilap

Volumn 150, Issue 35, 2009, Pages 1637-1647

  Gero, László ^a   Gyimesi, András ^b   Hidvégi, Tibor ^c   Jánosi, István ^d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b II Belgyógyászat ^*  (Hungary)

^c Petz Aladar Megyei Oktato Korhaz   (Hungary)

^d Planiméter Kft   (Hungary)

Author keywords

Biphasic aspart insulin; Biphasic human insulin; Cardiovascular risk factors; HbA1c; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; GLUCOSE BLOOD LEVEL; HUNGARY; HYPOGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; RISK FACTOR; TIME; WEIGHT GAIN;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HUNGARY; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; WEIGHT GAIN;

EID: 70350038156     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28705     Document Type: Article

References (25)

1. Wild, S., Roglic, G., Green, A. is mtsai: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Dia-bet. Care, 2004, 27, 1047-1053.
2. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993, 329, 977-986.
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patient with type 2 diabetes. Lancet, 1998, 352, 837-853.
4. Chiasson, J. L., Josse, R. G., Gomis, R. is mtsai: For The STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM Trial. JAMA, 2003, 290, 486-494.
5. Hanefeld, M., Cagatay, M., Petrowitsch, T. is mtsai: Acarbose reduces the risk for myocardial infarction in type 2 diabetic pa- tients: meta-analysis of seven long-term studies. Eur. Heart J., 2004, 25, 10-16.
6. Ceriello, A.: Post-prandial hyperglycemia and diabetes complications: is it time to treat? Diabetes, 2005, 54, 1-7.
7. Jacobsen, L. V, Sogaard, B., Riis, A.: Pharmacokinetics and pharmacodynamics of a premixed formulation of a soluble and protamine-retarded insulin aspart. Eur. J. Clin. Pharmacol., 2000, 56, 399-103.
8. Gough, S. C. L., Tibaldi, J.: Biphasic insulin aspart in type 2 diabetes mellitus. An evidence-based medicine review. Clin. Drug. Invest., 2007, 27, 299-324.
9. Lammert, M., Palmer, A., Roze, S. is mtsai: Decreased rates of major hypoglycaemic events lead to improved long term cost effectiveness of biphasic insulin aspart 30/70 versus biphasic human insulin 30 in type 2 diabetic subjects in Danish, Finnish, German, Norwegian, Spanish, Swedish and UK settings. Value Health, 2004, 7, 649.
10. -38/2007. (VII. 25.) EiiM-rendelettel m6dositott 32/2004. (IV 26.) ESzCsM-rendelet 2. meliaiet 3. b) Magyar Kozlciny 2007/98. szam.
11. Kapitza, C, Rave, K., Ostrowski, K. is mtsai: Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. Diab. Med., 2004, 21, 500-501.
12. Boehm, B., Home, P., Behrend, C. is mtsai: Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diab. Med., 2002, 19, 393-399.
13. Boehm, B. O., Vaz,J. A., Brondsted, L. ismtsa: Long-term efficacy and safety of biphasic human insulin aspart in patients with type 2 diabetes. Eur. J. Int. Med., 2004, 15, 496-502.
14. Raskin, P., Chaykin, L., Braceras, R. is mtsai: Biphasic insulin aspart 30 added to metformin/pioglitazone therapy enables 50% of type 2 diabetes subjects with HbAlc 8.0% to achieve the IDF goal of HbAlc
15. Garber, A. J., Wahlen, J., Wahl, T. is mtsai: Attainment of glyce-mic goal in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diab. Obes. Metab., 2006, 8, 58-66.
16. Holman, R. R., Thome, K. I., Farmer, A. J. is mtsai for the 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N. Engl. J. Med., 2007, 357, 1-15.
17. Editorial. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Br. Med. J., 2007, 335, 806-808.
18. Ligthelm, R. J., Borzi, V, Gumprecht, J. is mtsai: Importance of observational studies in clinical practice. Clin. Ther., 2007, 29, 1284-1292.
19. Shestakova, M., Bech, O. M., Momani, M. S.: Study design and baseline characteristics of patients in the PRESENT study. Diab. Res. Clin. Pract., 2008, 81S, S3-S9.
20. Gao, J., Guo, X. H., Vaz, J. A. for the PRESENT Study Group: Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT Study. Diab. Obes. Metab., 2009, 11, 33-40.
21. Khutsoane, D., Sharma, S. K., Almustafa, M. is mtsai for the PRESENT Study Group: Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diab. Obes. Metab., 2008, 10, 212-222.
22. Valensi, P., Benroubi, M., Borzi, V. is mtsai on behalf of the IMPROVE Study Group Expert Panel: The IMPROVE study -a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int. J. Clin. Pract., 2008, 62, 1809-1819.
23. Valensi, P., Benroubi, M., Borzi, V is mtsai on behalf of the IMPROVE Study Group Expert Panel: Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int. J. Clin. Pract., 2009, 63, 522-531.
24. Mark L., Zamolyi K., Pados Gy. is mtsai: C616rt6kek el6r6se lipidcsokkentc'i kezeIs soran - Magyarorszag 2004. Orv. Hetil., 2005, 146, 147-152.
25. Paragh Gy., Pados Gy., Karddi I. is mtsai: Mennyiben valosulnak meg a terapias konszenzus konferencia iranyelvei? - CfiL program. Metabolizmus, 2005, 3, 1-6.